Peijia Medical Limited
沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL FOR REGISTRATION APPLICATION OF Fastunnel® DELIVERY BALLOON DILATION CATHETER

This announcement is made by Peijia Medical Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on May 20, 2022, the Group received the approval from the National Medical Products Administration of the PRC (國家藥品監督管理局)(the "**NMPA**") for the registration application of Fastunnel® Delivery Balloon Dilation Catheter (formerly named as Neway™ Balloon Microcatheter), making it the Group's thirteenth NMPA approved neurointerventional product.

Fastunnel® Delivery Balloon Dilation Catheter is an innovative product developed by Achieva Medical ("**Achieva**"), a wholly-owned subsidiary of the Company, designed for treating intracranial atherosclerotic disease ("**ICAD**"). As the first medical device in China which can realize balloon dilation and stent delivery at the same time, its unique "zero exchange" technology will usher a new era of ICAD treatment. Fastunnel® Delivery Balloon Dilation Catheter adopts an integrated design combining the features of both balloon dilation catheter and microcatheter, which can reduce the frequency of device exchange and improve the safety of the procedure. The balloon uses Pebax semi-compliant materials to achieve steady shape and safe expansion. The device is available in two sizes with lumens of 0.017 and 0.021 inches, both of which are compatible with the intracranial stent systems. Meanwhile, the stainless steel structure reinforces the entire device, and thus improves the trackability of the catheter and the deliverability of the intracranial stent systems. In addition, the 150cm delivery system is compatible with an intermediate catheter length of 135cm and below.

ICAD is one of the most common causes of ischemic stroke in China, with the characteristics of high incidence and recurrence rates. During the endovascular treatment of ICAD, more exchange steps (if any) may lead to more complications such as vessel rupture, intracranial hemorrhage and vascular dissection. The innovative design of the Fastunnel® Delivery Balloon Dilation Catheter is closely aligned with the clinical needs, and is able to significantly simplify the operational procedures, reduce risks during the procedures, improve the safety of the procedures and reduce procedural complications of the patients.

As of this date, with regard to ICAD, Achieva's product lines have covered a number of devices, including SacSpeed® Balloon Dilatation Catheter, Fastunnel® Delivery Balloon Dilation Catheter, Tethys® Intermediate Catheter, Presgo® Micro Guidewire and Presgo® Microcatheter. Achieva will continue to enrich the product deployment in the aspect of ischemic stroke, facilitate the construction of domestic stroke centers and popularize the interventional treatment of ischemic stroke patients.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET Fastunnel® DELIVERY BALLOON DILATION CATHETER SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, May 22, 2022

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.